This is also a notable statement from the article IMO (a ramp of sales in Japan, now that the trial results are in):
"Vitrolife, in particular, has been running real-world utilisation testing in Japan for over a year—and had been waiting for clinical data before ramping up sales."
Japan is a potential immediate source of sustained income and an entry into a significant market while CE Mark (Europe), TGA (Australia), and CDSCO (India) approvals are sought.
This is also a notable statement from the article IMO (a ramp of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.917M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $84.84K | 17.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1066000 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 7314008 | 12 |
View Market Depth
| Last trade - 15.13pm 23/04/2025 (20 minute delay) ? |
| MEM (ASX) Chart |